A retrospective study to describe characteristics and six-month outcomes in patients with rheumatoid arthritis initiating Upadacitinib in a real-world setting from Corona Registry
Latest Information Update: 20 Jun 2021
At a glance
- Drugs Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 20 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism